Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F McDermott

Showing results (501-510 of 567) with videos related to

Pageof 57
Sort By:
Journal of the American Academy of Child and Adolescent Psychiatry|December 6, 2005
The National Center on Indigenous Hawaiian Behavioral Health study of prevalence of psychiatric disorders in native Hawaiian adolescentsNaleen N Andrade, Earl S Hishinuma, John F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge ConferenceMichael B Atkins, Marc S Ernstoff, Robert A Figlin, et al.
Molecular Cancer Therapeutics|October 17, 2014
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanomaDavid J Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, et al.
Nature Communications|September 27, 2019
Metabolomic adaptations and correlates of survival to immune checkpoint blockadeHaoxin Li, Kevin Bullock, Carino Gurjao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2019
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical TrialJean-Christophe Pignon, Opeyemi Jegede, Sachet A Shukla, et al.
European Urology|March 8, 2021
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical TrialThomas Powles, Michael B Atkins, Bernard Escudier, et al.
The Lancet. Oncology|September 14, 2016
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trialF Stephen Hodi, Jason Chesney, Anna C Pavlick, et al.
Cancer|January 19, 2010
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North AmericaWalter M Stadler, Robert A Figlin, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 TrialMeredith M Regan, Opeyemi A Jegede, Charlene M Mantia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell CarcinomaDavid F McDermott, Jae-Lyun Lee, Georg A Bjarnason, et al.
Pageof 57

Showing results (501-510 of 567) with videos related to

Sort By:
Pageof 57
Journal of the American Academy of Child and Adolescent Psychiatry|December 6, 2005
The National Center on Indigenous Hawaiian Behavioral Health study of prevalence of psychiatric disorders in native Hawaiian adolescentsNaleen N Andrade, Earl S Hishinuma, John F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge ConferenceMichael B Atkins, Marc S Ernstoff, Robert A Figlin, et al.
Molecular Cancer Therapeutics|October 17, 2014
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanomaDavid J Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, et al.
Nature Communications|September 27, 2019
Metabolomic adaptations and correlates of survival to immune checkpoint blockadeHaoxin Li, Kevin Bullock, Carino Gurjao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2019
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical TrialJean-Christophe Pignon, Opeyemi Jegede, Sachet A Shukla, et al.
European Urology|March 8, 2021
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical TrialThomas Powles, Michael B Atkins, Bernard Escudier, et al.
The Lancet. Oncology|September 14, 2016
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trialF Stephen Hodi, Jason Chesney, Anna C Pavlick, et al.
Cancer|January 19, 2010
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North AmericaWalter M Stadler, Robert A Figlin, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 TrialMeredith M Regan, Opeyemi A Jegede, Charlene M Mantia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2021
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell CarcinomaDavid F McDermott, Jae-Lyun Lee, Georg A Bjarnason, et al.
Pageof 57